These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 14627671)

  • 1. Analysis of the Birt-Hogg-Dubé (BHD) tumour suppressor gene in sporadic renal cell carcinoma and colorectal cancer.
    da Silva NF; Gentle D; Hesson LB; Morton DG; Latif F; Maher ER
    J Med Genet; 2003 Nov; 40(11):820-4. PubMed ID: 14627671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of BHD in sporadic renal tumors.
    Khoo SK; Kahnoski K; Sugimura J; Petillo D; Chen J; Shockley K; Ludlow J; Knapp R; Giraud S; Richard S; Nordenskjöld M; Teh BT
    Cancer Res; 2003 Aug; 63(15):4583-7. PubMed ID: 12907635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and characterization of Birt-Hogg-Dubé associated renal carcinoma.
    Murakami T; Sano F; Huang Y; Komiya A; Baba M; Osada Y; Nagashima Y; Kondo K; Nakaigawa N; Miura T; Kubota Y; Yao M; Kishida T
    J Pathol; 2007 Apr; 211(5):524-531. PubMed ID: 17323425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Birt-Hogg-Dubé gene mutations in human endometrial carcinomas with microsatellite instability.
    Fujii H; Jiang W; Matsumoto T; Miyai K; Sashara K; Ohtsuji N; Hino O
    J Pathol; 2006 Jul; 209(3):328-35. PubMed ID: 16691634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of the Birt-Hogg-Dube tumour suppressor gene (FLCN) in familial and sporadic colorectal cancer.
    Nahorski MS; Lim DH; Martin L; Gille JJ; McKay K; Rehal PK; Ploeger HM; van Steensel M; Tomlinson IP; Latif F; Menko FH; Maher ER
    J Med Genet; 2010 Jun; 47(6):385-90. PubMed ID: 20522427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinctive expression patterns of glycoprotein non-metastatic B and folliculin in renal tumors in patients with Birt-Hogg-Dubé syndrome.
    Furuya M; Hong SB; Tanaka R; Kuroda N; Nagashima Y; Nagahama K; Suyama T; Yao M; Nakatani Y
    Cancer Sci; 2015 Mar; 106(3):315-23. PubMed ID: 25594584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorescent and chromogenic in situ hybridization of CEN17q as a potent useful diagnostic marker for Birt-Hogg-Dubé syndrome-associated chromophobe renal cell carcinomas.
    Kato I; Iribe Y; Nagashima Y; Kuroda N; Tanaka R; Nakatani Y; Hasumi H; Yao M; Furuya M
    Hum Pathol; 2016 Jun; 52():74-82. PubMed ID: 26980015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment and characterization of BHD-F59RSVT, an immortalized cell line derived from a renal cell carcinoma in a patient with Birt-Hogg-Dubé syndrome.
    Furuya M; Hasumi H; Baba M; Tanaka R; Iribe Y; Onishi T; Nagashima Y; Nakatani Y; Isono Y; Yao M
    Lab Invest; 2017 Mar; 97(3):343-351. PubMed ID: 27991910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are lung cysts in renal cell cancer (RCC) patients an indication for FLCN mutation analysis?
    Johannesma PC; Houweling AC; Menko FH; van de Beek I; Reinhard R; Gille JJ; van Waesberghe JT; Thunnissen E; Starink TM; Postmus PE; van Moorselaar RJ
    Fam Cancer; 2016 Apr; 15(2):297-300. PubMed ID: 26603437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports.
    Toro JR; Wei MH; Glenn GM; Weinreich M; Toure O; Vocke C; Turner M; Choyke P; Merino MJ; Pinto PA; Steinberg SM; Schmidt LS; Linehan WM
    J Med Genet; 2008 Jun; 45(6):321-31. PubMed ID: 18234728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel mutations in the BHD gene and absence of loss of heterozygosity in fibrofolliculomas of Birt-Hogg-Dubé patients.
    van Steensel MA; Verstraeten VL; Frank J; Kelleners-Smeets NW; Poblete-Gutiérrez P; Marcus-Soekarman D; Bladergroen RS; Steijlen PM; van Geel M
    J Invest Dermatol; 2007 Mar; 127(3):588-93. PubMed ID: 17124507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management.
    Maher ER
    World J Urol; 2018 Dec; 36(12):1891-1898. PubMed ID: 29680948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
    Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
    Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of the Birt Hogg Dube gene in patients with multiple lung cysts and recurrent pneumothorax.
    Gunji Y; Akiyoshi T; Sato T; Kurihara M; Tominaga S; Takahashi K; Seyama K
    J Med Genet; 2007 Sep; 44(9):588-93. PubMed ID: 17496196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic targeting the loss of the birt-hogg-dube suppressor gene.
    Lu X; Wei W; Fenton J; Nahorski MS; Rabai E; Reiman A; Seabra L; Nagy Z; Latif F; Maher ER
    Mol Cancer Ther; 2011 Jan; 10(1):80-9. PubMed ID: 21220493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dubé tumour suppressor gene (FLCN).
    Lu X; Boora U; Seabra L; Rabai EM; Fenton J; Reiman A; Nagy Z; Maher ER
    Oncogene; 2014 Feb; 33(8):956-65. PubMed ID: 23416984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Report of Birt-Hogg-Dubé Syndrome: Germline Mutations of FLCN Detected in Patients With Renal Cancer and Thyroid Cancer.
    Dong L; Gao M; Hao WJ; Zheng XQ; Li YG; Li XL; Yu Y
    Medicine (Baltimore); 2016 May; 95(22):e3695. PubMed ID: 27258496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and genetic studies of Birt-Hogg-Dubé syndrome.
    Khoo SK; Giraud S; Kahnoski K; Chen J; Motorna O; Nickolov R; Binet O; Lambert D; Friedel J; Lévy R; Ferlicot S; Wolkenstein P; Hammel P; Bergerheim U; Hedblad MA; Bradley M; Teh BT; Nordenskjöld M; Richard S
    J Med Genet; 2002 Dec; 39(12):906-12. PubMed ID: 12471204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dubé-associated renal tumors.
    Vocke CD; Yang Y; Pavlovich CP; Schmidt LS; Nickerson ML; Torres-Cabala CA; Merino MJ; Walther MM; Zbar B; Linehan WM
    J Natl Cancer Inst; 2005 Jun; 97(12):931-5. PubMed ID: 15956655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.